A practical reference on circadian clock: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-19. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Michael Ray Dibdin Heseltine, Baron Heseltine (; born 21 March 1933) is a British politician. Having begun his career as a property developer, he became one of the founders of the publishing house Haymarket Media Group in 1957. Heseltine served as a Conservative Member of Parliament from 1966 to 2001. He was a prominent figure in the governments of Margaret Thatcher and John Major, and served as Deputy Prime Minister and First Secretary of State under Major from 1995 to 1997. Heseltine entered the Cabinet in 1979 as Secretary of State for the Environment, where he promoted the "Right to Buy" campaign that allowed people to purchase their council houses. He was considered an adept media performer and a charismatic minister, although he was frequently at odds with Thatcher on economic issues. He was one of the most visible "wets", whose "One Nation" views were epitomised by his support for the regeneration of Liverpool in the early 1980s when it was facing economic collapse; this later earned him the award of Freeman of the City of Liverpool in 2012. As Secretary of State for Defence from 1983 to 1986, he was instrumental in the political battle against the Campaign for Nuclear Disarmament. He resigned from the Cabinet in 1986 over the Westland affair and returned to the backbenches, becoming a vocal critic of Thatcher, mostly because of her Eurosceptic views and confrontational approach in Parliament.
Although it is not entirely clear which gene causes the resistance phenotype, there is strong evidence supporting the correlation between a mutation in the membrane transporter ABCC2 and Bt resistance. Other studies with greenhouse-evolved population of Bt resistant cabbage looper demonstrate that the downregulation of the aminopeptidase N, APN1, results in its resistance.
With the ability to form porous glasses as platelets, membrane technology is another important area of application. Hyper filtration of sea – and brackish water and ultra filtration in "downstream process" are but two. Additionally, they are often appropriate as a carrier for catalysts. For example, the olefin – metathesis was realized on the system metal – metal oxide/porous glass. Porous glasses can be used as membrane reactors as well, again because of their high mechanical, thermal and chemical stability. Membrane reactors can improve conversion of limited balance reactions, while one reaction product is removed by a selective membrane. For example, in the decomposition of hydrogen sulfide on a catalyst in a glass capillary, the conversion by reaction was higher with glass capillary than without.
Michael Bailey, who found that homosexuality had a genetic possibility; Laura Allen and Roger Gorski of UCLA had conducted research on the anterior commissure; molecular geneticist Cassandra Smith; the editor of The Arizona Republic. Directed by Jeremy Taylor, produced by Oliver Morse, made by Windfall Films 18 October Antichaos, about order out of chaos, with Ian Stewart of the University of Warwick; Canadian mathematician Brian Goodwin of the Open University, and emergence; the American biologist Stuart Kauffman of the Santa Fe Institute, and Boolean networks; the Danish theoretical physicist Per Bak of Brookhaven National Laboratory; Christopher Langton of the Santa Fe Institute; the American ecologist Tom Ray of the University of Delaware; the economist W. Brian Arthur of Stanford University; J. Doyne Farmer of the Prediction Company; and the American physicist Thomas Valone (a writer on bioelectromagnetics) of the University of New Mexico. Narrated by Alun Lewis, directed by Yavar Abbas, produced by Geoff Deehan, made by Union Pictures 25 October The Strange Case of Crop Circles 2, showing what had changed from the previous documentary broadcast on 27 October 1991. Directed by Jill Freeman, produced by Michael Wills, made by Juniper Productions 1 November Zen on Wheels, about how Japanese car manufacturers moved a team to Newport Beach, California at the Toyota Calty Design Research, to find out what appealed to buyers of BMW and Mercedes cars, which resulted in the Lexus LS, which outsold Mercedes-Benz and BMW.
== Early life == Darshan Ranganathan was born as Darshan Markan on 4 June 1941 to Vidyavati Markan and Shanti Swarup in Delhi. She was educated in Delhi and received a Ph.D. in chemistry from Delhi University in 1967. First hired as a lecturer, she became head of the Chemistry Department at Miranda College, Delhi, and went on to receive an 1851 Research Fellowship from the Royal Commission for the Exhibition of 1851, to enable her to conduct postdoctoral work at Imperial College London with Professor D.H.R. Barton.
Sources: en.wikipedia.org
=== Animal synthesis === There is some information on serum vitamin C concentrations maintained in animal species that are able to synthesize vitamin C. One study of several breeds of dogs reported an average of 35.9 μmol/L. A report on goats, sheep and cattle reported ranges of 100–110, 265–270 and 160–350 μmol/L, respectively. The biosynthesis of ascorbic acid in vertebrates starts with the formation of UDP-glucuronic acid. UDP-glucuronic acid is formed when UDP-glucose undergoes two oxidations catalyzed by the enzyme UDP-glucose 6-dehydrogenase. UDP-glucose 6-dehydrogenase uses the co-factor NAD+ as the electron acceptor. The transferase UDP-glucuronate pyrophosphorylase removes a UMP and glucuronokinase, with the cofactor ADP, removes the final phosphate leading to d-glucuronic acid. The aldehyde group of this compound is reduced to a primary alcohol using the enzyme glucuronate reductase and the cofactor NADPH, yielding l-gulonic acid. This is followed by lactone formation—utilizing the hydrolase gluconolactonase—between the carbonyl on C1 and hydroxyl group on C4. l-Gulonolactone then reacts with oxygen, catalyzed by the enzyme L-gulonolactone oxidase (which is nonfunctional in humans and other Haplorrhini primates; see Unitary pseudogenes) and the cofactor FAD+. This reaction produces 2-oxogulonolactone (2-keto-gulonolactone), which spontaneously undergoes enolization to form ascorbic acid. Reptiles and older orders of birds make ascorbic acid in their kidneys. Recent orders of birds and most mammals make ascorbic acid in their liver.
Central nervous system: fatigue, dizziness, drowsiness, lightheadedness, confusion, nightmares, agitation, increased anxiety, difficulty sleeping, seizures (infrequently), temporary confusion (delirium), rarely induction of hypomania and psychosis, extrapyramidal side effects (rarely), abuse in patients with polytoxicomania (rarely), ringing in the ears (tinnitus) Anticholinergic: dry mouth, constipation, even ileus (rarely), difficulties in urinating, sweating, precipitation of glaucoma Antiadrenergic: Low blood pressure, (if patient arises too fast from the lying/sitting position to standing—known as orthostatic hypotension), abnormal heart rhythms (e.g., sinus tachycardia, bradycardia, and atrioventricular block) Allergic/toxic: skin rash, photosensitivity, liver damage of the cholestatic type (rarely), hepatitis (extremely rare), leuko- or thrombocytopenia (rarely), agranulocytosis (very rarely), hypoplastic anemia (rarely) Others: frequently increased appetite and weight gain, rarely nausea, rarely high blood pressure. May increase or decrease liver enzyme levels in the blood of some people. The side effects of low-dose doxepin for insomnia in long-term clinical trials (28 to 85 days) in adults and elderly people were as follows:
Imetelstat, sold under the brand name Rytelo, is an anti-cancer medication used for the treatment of myelodysplastic syndromes with transfusion-dependent anemia. Imetelstat is an oligonucleotide telomerase inhibitor. By blocking telomerase activity, imetelstat causes telomere shortening, inhibits the proliferation of malignant stem and progenitor cells and induces cell death, ultimately leading to a reduction in malignant clones. The most common adverse reactions include decreased platelets, decreased white blood cells, decreased neutrophils, increased aspartate aminotransferase, increased alkaline phosphatase, increased alanine aminotransferase, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache. Imetelstat was approved for medical use in the United States in June 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Lys arylation Similar to cysteine, lysine N-arylation could be achieved through Pd OACs with different dialkylbiaryl phosphine ligands. Due to weaker nucleophilicity and slower reductive elimination rate compared to cysteine, the selection of supporting ligands is shown to be critical. The bulky BrettPhos and t-BuBrettPhos ligands in conjunction with mildly basic sodium phenoxide have been used as the strategy to functionalize lysines on peptide substrates. The reaction happens in mild conditions and is selective over most other nucleophilic amino acid residues.
Sources: en.wikipedia.org
The tonic FSH and LH pulses sufficiently stimulate the theca cells of the follicle to produce androgen substrates for granulosa cell aromatase and induces cytochrome P450 enzymes that can produce progesterone later in the luteal phase. Androgen substrates from the theca cells are used by the enlarging granulosa cells to produce more estradiol. At mid-follicular phase, GnSAF bioactivity gradually declines as the dominant follicle is established and the small subordinate follicles undergo atresia. The development of the dominant follicle and regression of small non-dominant follicles is supported by increasing estradiol secretion. Towards the end of the follicular phase, GnSAF bioactivity is at its lowest due to the absence of small antral follicles. Estradiol secretion from the dominant follicle exponentially increases and exceeds a threshold which switches estradiol feedback on GnRH pulse frequency from negative to positive. Pituitary sensitivity to GnRH is restored.
In 2009, Cullis co-founded a company called Acuitas Therapeutics to commercialize his LNP research; Acuitas worked on developing LNPs for Alnylam Pharmaceuticals's siRNA drugs. In 2018, the FDA approved Alnylam's siRNA drug Onpattro (patisiran), the first drug to use LNPs as the drug delivery system. By that point in time, siRNA drug developers like Alnylam were already looking at other options for future drugs like chemical conjugate systems, but during the 2010s, the earlier research into using LNPs for siRNA became a foundation for new research into using LNPs for mRNA. Lipids intended for short siRNA strands did not work well for much longer mRNA strands, which led to extensive research during the mid-2010s into the creation of novel ionizable cationic lipids appropriate for mRNA. As of late 2020, several mRNA vaccines for SARS-CoV-2 use LNPs as their drug delivery system, including both the Moderna COVID-19 vaccine and the Pfizer–BioNTech COVID-19 vaccines. Moderna uses its own proprietary ionizable cationic lipid called SM-102, while Pfizer and BioNTech licensed an ionizable cationic lipid called ALC-0315 from Acuitas.
Likewise, in eukaryotes the maintenance of telomeres involves copying of an RNA template that is a constituent part of the telomerase ribonucleoprotein enzyme. Another cellular organelle, the vault, includes a ribonucleoprotein component, although the function of this organelle remains to be elucidated.
In biology, matrix (pl.: matrices) is the material (or tissue) in between cells within a eukaryotic organism. The structure of connective tissues is an extracellular matrix. Fingernails and toenails grow from matrices. It is found in various connective tissues. It serves as a jelly-like structure instead of cytoplasm in connective tissue.
=== Osteoid in bone tumors === Osteosarcoma: The most common primary malignant bone tumor, osteosarcoma is characterized by malignant cells that produce osteoid. Osteosarcoma is a primary malignant tumour of the skeleton characterized by the direct formation of immature bone or osteoid tissue by the tumour cells. The production of osteoid by tumor cells is the histological hallmark distinguishing osteosarcoma from other bone tumors. The malignant osteoid produced appears as irregular, immature structures in close proximity to malignant cells with enlarged hyperchromatic nuclei and abnormal mitotic figures. Osteoid osteoma: A benign bone-forming tumor characterized by formation of osteoid tissue, typically causing localized bone pain that worsens at night.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.